140 related articles for article (PubMed ID: 17004270)
61. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
62. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
63. Virtual screening and experimental verification to identify potential inhibitors of the ErmC methyltransferase responsible for bacterial resistance against macrolide antibiotics.
Feder M; Purta E; Koscinski L; Cubrilo S; Maravic Vlahovicek G; Bujnicki JM
ChemMedChem; 2008 Feb; 3(2):316-22. PubMed ID: 18038381
[TBL] [Abstract][Full Text] [Related]
64. 4-Substituted trinems as broad spectrum beta-lactamase inhibitors: structure-based design, synthesis, and biological activity.
Plantan I; Selic L; Mesar T; Anderluh PS; Oblak M; Prezelj A; Hesse L; Andrejasic M; Vilar M; Turk D; Kocijan A; Prevec T; Vilfan G; Kocjan D; Copar A; Urleb U; Solmajer T
J Med Chem; 2007 Aug; 50(17):4113-21. PubMed ID: 17665896
[TBL] [Abstract][Full Text] [Related]
65. Specificity of substrate recognition by type II dehydroquinases as revealed by binding of polyanions.
Evans LD; Roszak AW; Noble LJ; Robinson DA; Chalk PA; Matthews JL; Coggins JR; Price NC; Lapthorn AJ
FEBS Lett; 2002 Oct; 530(1-3):24-30. PubMed ID: 12387860
[TBL] [Abstract][Full Text] [Related]
66. Chemical Modification of a Dehydratase Enzyme Involved in Bacterial Virulence by an Ammonium Derivative: Evidence of its Active Site Covalent Adduct.
González-Bello C; Tizón L; Lence E; Otero JM; van Raaij MJ; Martinez-Guitian M; Beceiro A; Thompson P; Hawkins AR
J Am Chem Soc; 2015 Jul; 137(29):9333-43. PubMed ID: 26148116
[TBL] [Abstract][Full Text] [Related]
67. In vitro and ex vivo activity of new derivatives of acetohydroxyacid synthase inhibitors against Mycobacterium tuberculosis and non-tuberculous mycobacteria.
Sohn H; Lee KS; Ko YK; Ryu JW; Woo JC; Koo DW; Shin SJ; Ahn SJ; Shin AR; Song CH; Jo EK; Park JK; Kim HJ
Int J Antimicrob Agents; 2008 Jun; 31(6):567-71. PubMed ID: 18337064
[TBL] [Abstract][Full Text] [Related]
68. Comparative pharmacophore development for inhibitors of human and rat 5-alpha-reductase.
Faragalla J; Bremner J; Brown D; Griffith R; Heaton A
J Mol Graph Model; 2003 Sep; 22(1):83-92. PubMed ID: 12798393
[TBL] [Abstract][Full Text] [Related]
69. The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis.
Sacco E; Covarrubias AS; O'Hare HM; Carroll P; Eynard N; Jones TA; Parish T; Daffé M; Bäckbro K; Quémard A
Proc Natl Acad Sci U S A; 2007 Sep; 104(37):14628-33. PubMed ID: 17804795
[TBL] [Abstract][Full Text] [Related]
70. Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli.
Tasdemir D; Topaloglu B; Perozzo R; Brun R; O'Neill R; Carballeira NM; Zhang X; Tonge PJ; Linden A; Rüedi P
Bioorg Med Chem; 2007 Nov; 15(21):6834-45. PubMed ID: 17765547
[TBL] [Abstract][Full Text] [Related]
71. Recent advances in the discovery of 11beta-HSD1 inhibitors.
Boyle CD
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
[TBL] [Abstract][Full Text] [Related]
72. Crystal structure of Plasmodium falciparum spermidine synthase in complex with the substrate decarboxylated S-adenosylmethionine and the potent inhibitors 4MCHA and AdoDATO.
Dufe VT; Qiu W; Müller IB; Hui R; Walter RD; Al-Karadaghi S
J Mol Biol; 2007 Oct; 373(1):167-77. PubMed ID: 17822713
[TBL] [Abstract][Full Text] [Related]
73. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
[TBL] [Abstract][Full Text] [Related]
74. Molecular basis for the inhibition of β-hydroxyacyl-ACP dehydratase HadAB complex from Mycobacterium tuberculosis by flavonoid inhibitors.
Dong Y; Qiu X; Shaw N; Xu Y; Sun Y; Li X; Li J; Rao Z
Protein Cell; 2015 Jul; 6(7):504-17. PubMed ID: 26081470
[TBL] [Abstract][Full Text] [Related]
75. Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
Erion MD; Dang Q; Reddy MR; Kasibhatla SR; Huang J; Lipscomb WN; van Poelje PD
J Am Chem Soc; 2007 Dec; 129(50):15480-90. PubMed ID: 18041833
[TBL] [Abstract][Full Text] [Related]
76. Structure of 2-deoxy-scyllo-inosose synthase, a key enzyme in the biosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics, in complex with a mechanism-based inhibitor and NAD+.
Nango E; Kumasaka T; Hirayama T; Tanaka N; Eguchi T
Proteins; 2008 Feb; 70(2):517-27. PubMed ID: 17879343
[TBL] [Abstract][Full Text] [Related]
77. Irreversible inhibition of dihydrodipicolinate synthase by 4-oxo-heptenedioic acid analogues.
Boughton BA; Griffin MD; O'Donnell PA; Dobson RC; Perugini MA; Gerrard JA; Hutton CA
Bioorg Med Chem; 2008 Dec; 16(23):9975-83. PubMed ID: 18977662
[TBL] [Abstract][Full Text] [Related]
78. Conformationally constrained diketopimelic acid analogues as inhibitors of dihydrodipicolinate synthase.
Boughton BA; Dobson RC; Gerrard JA; Hutton CA
Bioorg Med Chem Lett; 2008 Jan; 18(2):460-3. PubMed ID: 18077163
[TBL] [Abstract][Full Text] [Related]
79. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
80. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors.
Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE
ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
